Anti-IDH2 antibody [5F11]
- KO Validated
- What is this?
Be the first to review this product! Submit a review
|
(48 Publications)
Mouse Monoclonal IDH2 antibody. Suitable for Flow Cyt, WB, IHC-P, ICC/IF and reacts with Human, Recombinant fragment - Human samples. Cited in 48 publications. Immunogen corresponding to Recombinant Fragment Protein within Human IDH2 aa 350-500.
View Alternative Names
IDH, ICD-M, IDP, NADP(+)-specific ICDH, Oxalosuccinate decarboxylase, IDH2
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-IDH2 antibody [5F11] (AB55271)
IDH2 antibody (ab55271) used in immunohistochemistry at 3ug/ml on formalin fixed and paraffin embedded human colon.
This image was generated using the ascites version of the product.
- Flow Cyt
Unknown
Flow Cytometry - Anti-IDH2 antibody [5F11] (AB55271)
Overlay histogram showing MCF7 cells stained with ab55271 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab55271, 1μg/1x106 cells) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2μg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in MCF7 cells fixed with 80% methanol (5 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.
This image was generated using the ascites version of the product.
- ICC/IF
Unknown
Immunocytochemistry/ Immunofluorescence - Anti-IDH2 antibody [5F11] (AB55271)
ICC/IF image of ab55271 stained Mcf7 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab55271, 10μg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43μM.
This image was generated using the ascites version of the product.
- WB
Lab
Western blot - Anti-IDH2 antibody [5F11] (AB55271)
False colour image of Western blot : Anti-IDH2 antibody [5F11] staining at 1/1000 dilution, shown in green; Rabbit Anti-GAPDH antibody [EPR16891] (ab181602) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab55271 was shown to bind specifically to IDH2. A band was observed at 48 kDa in wild-type Jurkat cell lysates with no signal observed at this size in IDH2 knockout cell line ab282331 (knockout cell lysate ab283148). To generate this image, wild-type and IDH2 knockout Jurkat cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4°C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (ab216777) at 1/20000 dilution.
All lanes:
Western blot - Anti-IDH2 antibody [5F11] (ab55271) at 1/1000 dilution
Lane 1:
Wild-type Jurkat cell lysate at 20 µg
Lane 2:
IDH2 knockout Jurkat cell lysate at 20 µg
Lane 2:
Western blot - Human IDH2 knockout Jurkat cell line (<a href='/en-us/products/cell-lines/human-idh2-knockout-jurkat-cell-line-ab282331'>ab282331</a>)
Lane 3:
MOLT-4 cell lysate at 20 µg
Lane 4:
HEK-293 cell lysate at 20 µg
Predicted band size: 50 kDa
Observed band size: 48 kDa
false
- WB
Lab
Western blot - Anti-IDH2 antibody [5F11] (AB55271)
Western blot : Anti-IDH2 antibody [5F11] (ab55271) staining at 1/1000 dilution, shown in green; Rabbit Anti-GAPDH antibody [EPR16891] (ab181602) loading control staining at 1/20000 dilution, shown in magenta. In Western blot, ab55271 was shown to bind specifically to IDH2. A band was observed at 51 kDa in wild-type A549 cell lysates with no signal observed at this size in IDH2 knockout cell line. To generate this image, wild-type and IDH2 knockout A549 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L 800CW and Goat anti-Rabbit IgG H&L 680RD at 1/20000 dilution.
All lanes:
Western blot - Anti-IDH2 antibody [5F11] (ab55271) at 1/1000 dilution
Lane 1:
Wild-type A549 cell lysate at 20 µg
Lane 2:
IDH2 knockout A549 cell lysate at 20 µg
Lane 3:
Wild-type Jurkat cell lysate at 20 µg
Lane 4:
IDH2 knockout Jurkat <a href='/en-us/products/cell-lines/human-idh2-knockout-jurkat-cell-line-ab282331'>ab282331</a> cell lysate at 20 µg
Secondary
All lanes:
Goat anti-Mouse IgG H&L 800CW and Goat anti-Rabbit IgG H&L 680RD at 1/20000 dilution
Observed band size: 51 kDa
false
- WB
Unknown
Western blot - Anti-IDH2 antibody [5F11] (AB55271)
Western blot against tagged recombinant protein immunogen using ab55271 IDH2 antibody at 1ug/ml. Predicted band size of immunogen is 37 kDa
This image was generated using the ascites version of the product.
All lanes:
Western blot - Anti-IDH2 antibody [5F11] (ab55271)
Predicted band size: 50 kDa
false
- WB
Unknown
Western blot - Anti-IDH2 antibody [5F11] (AB55271)
The blocking agent used is 5% milk.
This image was generated using the ascites version of the product.
All lanes:
Western blot - Anti-IDH2 antibody [5F11] (ab55271)
Lane 1:
IDH2 in transfected 293T cell line
Lane 2:
Non-transfected lysate
Predicted band size: 50 kDa
false
- WB
CiteAb
Western blot - Anti-IDH2 antibody [5F11] (AB55271)
Western Blotting using Anti-IDH2 antibody [5F11], ab55271. Publication image from Lee, W. D. et al., 2019, Nat Commun, 30903027. Legend direct from paper.
A quantitative view of mitochondrial and cytosolic fluxes in the TCA cycle and citrate metabolism under normoxia. a–d Mass-isotopomer labeling kinetics of citrate in mitochondria (a) and cytosol (b), and malate in mitochondria (c) and cytosol (d) when feeding HeLa cells with [U-13C]-glutamine under standard normoxic conditions. e Measured isotopic labeling ratio in HeLa cells for citrate m + 5 /m + 4 and malate m + 3 /m + 4 in media (red) in comparison to the expected labeling via computational simulation, considering the measured labeling kinetics of citrate and malate in mitochondria (green) and cytosol (orange). f Gibbs free energy of mitochondrial (IDH2/3) and cytosolic (IDH1) IDH isozymes (in the oxidative direction) in HeLa cells under normoxia (green) and hypoxia (red). g Mitochondrial and cytosolic fluxes, showing percentage from citrate synthase flux (which is 0.48 mM h−1). Arrow represents the direction of net flux; number represents net flux in the direction of the arrow and number in parenthesis correspond to the backward flux. Confidence intervals for estimated fluxes are shown in Supplementary Data 8. h The measured mass-isotopomer distribution of palmitate when feeding cells with [U-13C]-glutamine (green) is consistent with the simulated fit (orange). For the simulation, acetyl-CoA labeling was assumed to follow a binomial distribution with a probability of 7.1% having m + 2 labeling form. i Validation of the method based on knock-down of IDH1 or IDH2 genes and following citrate isotopic labeling after feeding cells with [U-13C]-glutamine. Upon IDH1 knockdown, the ratios between citrate m + 5 and m + 4 in mitochondria and cytosol are similar, indicating that all reductive glutamine flux occurred in mitochondria (where citrate m + 4 is produced from malate m + 4). Meanwhile, IDH2 knockdown resulted in a higher citrate m + 5 to m + 4 ratio in cytosol, indicating that reductive IDH1 remains active. n.s. not significant. *P < 0.05 and **P < 0.01 by two-sample t-test. Data are mean ± SD, n = 3 independent biological replicates
false
Reactivity data
Product details
Properties and storage information
Form
Purity
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The IDH2 enzyme facilitates cellular metabolism by producing NADPH critical for biosynthesis and antioxidant defense. It functions within the oxidative decarboxylation of isocitrate providing reducing equivalents to keep cellular redox balance. Although not part of a larger enzymatic complex IDH2 acts synergistically with other metabolic enzymes to maintain cellular biochemical pathways.
Pathways
The IDH2 protein participates in the citric acid cycle and redox homeostasis. IDH2 contributes to the tricarboxylic acid (TCA) pathway coupling with other TCA components such as citrate synthase and aconitase. Within the redox pathway it influences glucose metabolism via its link with enzymes like NADPH oxidase ensuring a steady supply of NADPH for biosynthetic reactions.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (48)
Recent publications for all applications. Explore the full list and refine your search
Nature communications 15:3445 PubMed38658533
2024
Applications
Unspecified application
Species
Unspecified reactive species
Biomedicines 11: PubMed36831011
2023
Applications
Unspecified application
Species
Unspecified reactive species
The EMBO journal 42:e110620 PubMed36637036
2023
Applications
Unspecified application
Species
Unspecified reactive species
Journal of biochemical and molecular toxicology 37:e23289 PubMed36536497
2022
Applications
Unspecified application
Species
Unspecified reactive species
Science advances 8:eabp8293 PubMed36525494
2022
Applications
Unspecified application
Species
Unspecified reactive species
Cancer discovery 13:170-193 PubMed36222845
2022
Applications
Unspecified application
Species
Unspecified reactive species
iScience 25:104823 PubMed35992092
2022
Applications
Unspecified application
Species
Unspecified reactive species
Leukemia 36:1150-1159 PubMed34997181
2022
Applications
Unspecified application
Species
Unspecified reactive species
eLife 10: PubMed34874009
2021
Applications
Unspecified application
Species
Unspecified reactive species
Cancers 13: PubMed34680392
2021
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com